Objective:PIK3CA is
the most common pathway affected by mutations in breast cancer. PIK3CA/PTEN pathway is under
intense investigation as a possible target for molecular therapy. Dysregulation PIK3CA/PTEN
pathway is a substantial mechanism for the development of resistance to
anti-HER2 therapy. Therefore, we aimed to study the PIK3CA/PTEN in breast cancer
patients in Saudi population. Methods: We applied PTEN
immunohistochemistry on 98 patients. Then, we applied next-generation
sequencing to determine the genetic variations associated with the development
of breast cancer and their correlations with clinicopathological variables. Results: PTEN expression was
significantly correlated with lymph node metastasis (LNM), tumor stage,
lymphovascular invasion (LVI) andtriple negative breast cancer (TNBC). The
prevalence of the PIK3CA mutation was 33.3% of cases and it was significantly associated with LNM, tumor
stage, and with PTEN expression. c-METmutation was
References
[1]
Siegel, R.L., Miller, K.D. and Jemal, A. (2019) Cancer Statistics, 2019. CA: A Cancer Journal for Clinicians, 69, 7-34. https://doi.org/10.3322/caac.21551
[2]
Alotaibi, R.M., Rezk, H.R., Juliana, C.I. and Guure, C. (2018) Breast Cancer Mortality in Saudi Arabia: Modelling Observed and Unobserved Factors. PLoS ONE, 13, e0206148. https://doi.org/10.1371/journal.pone.0206148
[3]
Herzallah, H.K., Antonisamy, B.R., Shafee, M.H. and Al-Otaibi, S.T. (2019) Temporal Trends in the Incidence and Demographics of Cancers, Communicable Diseases, and Non-Communicable Diseases in Saudi Arabia over the Last Decade. Saudi Medical Journal, 40, 277-286. https://doi.org/10.15537/smj.2019.3.23585
[4]
Alnegheimish, N.A., Alshatwi, R.A., Alhefdhi, R.M., Arafah, M.M., AlRikabi, A.C. and Husain, S. (2016) Molecular Subtypes of Breast Carcinoma in Saudi Arabia. A Retrospective Study. Saudi Medical Journal, 37, 506-512.
https://doi.org/10.15537/smj.2016.5.15000
[5]
Testa, U., Castelli, G. and Pelosi, E. (2020) Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. Medical Sciences (Basel, Switzerland), 8, 18. https://doi.org/10.3390/medsci8010018
[6]
Bai, J., Chen, W.-B., Zhang, X.-Y., Kang, X.-N., Jin, L.-J., Zhang, H., et al. (2020) HIF-2α Regulates CD44 to Promote Cancer Stem Cell Activation in Triple-Negative Breast Cancer via PI3K/AKT/mTOR Signaling. The World Journal of Stem Cells, 12, 87-99. https://doi.org/10.4252/wjsc.v12.i1.87
[7]
Wang, L.-L., Hao, S., Zhang, S., Guo, L.-J., Hu, C.-Y., Zhang, G., et al. (2017) PTEN/PI3K/AKT Protein Expression Is Related to Clinicopathological Features and Prognosis in Breast Cancer with Axillary Lymph Node Metastases. Human Pathology, 61, 49-57. https://doi.org/10.1016/j.humpath.2016.07.040
[8]
Boyault, S., Drouet, Y., Navarro, C., Bachelot, T., Lasset, C., Treilleux, I., et al. (2012) Mutational Characterization of Individual Breast Tumors: TP53 and PI3K Pathway Genes Are Frequently and Distinctively Mutated in Different Subtypes. Breast Cancer Research and Treatment, 132, 29-39.
https://doi.org/10.1007/s10549-011-1518-y
[9]
Song, M.S., Salmena, L. and Pandolfi, P.P. (2012) The Functions and Regulation of the PTEN Tumour Suppressor. Nature Reviews Molecular Cell Biology, 13, 283-296.
https://doi.org/10.1038/nrm3330
[10]
Gherardi, E., Birchmeier, W., Birchmeier, C. and Vande Woude, G. (2012) Targeting MET in Cancer: Rationale and Progress. Nature Reviews Cancer, 12, 89-103.
https://doi.org/10.1038/nrc3205
[11]
Xu, K., Usary, J., Kousis, P.C., Prat, A., Wang, D.-Y., Adams, J.R., et al. (2012) Lunatic Fringe Deficiency Cooperates with the Met/Caveolin Gene Amplicon to Induce Basal-Like Breast Cancer. Cancer Cell, 21, 626-641.
https://doi.org/10.1016/j.ccr.2012.03.041
[12]
Ho-Yen, C.M., Jones, J.L. and Kermorgant, S. (2015) The Clinical and Functional Significance of c-Met in Breast Cancer: A Review. Breast Cancer Research, 17, 52.
https://doi.org/10.1186/s13058-015-0547-6
[13]
Patruno, R., Marech, I., Zizzo, N., Ammendola, M., Nardulli, P., Gadaleta, C., et al. (2014) c-Kit Expression, Angiogenesis, and Grading in Canine Mast Cell Tumour: A Unique Model to Study c-Kit Driven Human Malignancies. BioMed Research International, 2014, Article ID: 730246. https://doi.org/10.1155/2014/730246
[14]
Ribatti, D. and Ranieri, G. (2015) Tryptase, a Novel Angiogenic Factor Stored in Mast Cell Granules. Experimental Cell Research, 332, 157-162.
https://doi.org/10.1016/j.yexcr.2014.11.014
[15]
Marech, I., Ammendola, M., Leporini, C., Patruno, R., Luposella, M., Zizzo, N., et al. (2018) C-Kit Receptor and Tryptase Expressing Mast Cells Correlate with Angiogenesis in Breast Cancer Patients. Oncotarget, 9, 7918-7927.
https://doi.org/10.18632/oncotarget.23722
[16]
Elston, C.W. and Ellis, I.O. (2002) Pathological Prognostic Factors in Breast Cancer. I. The Value of Histological Grade in Breast Cancer: Experience from a Large Study with Long-Term Follow-Up. Histopathology, 41, 154-161.
https://doi.org/10.1046/j.1365-2559.2002.14691.x
[17]
Hammond, M.E., Hayes, D.F. and Wolff, A.C. (2011) Clinical Notice for American Society of Clinical Oncology—College of American Pathologists Guideline Recommendations on ER/PgR and HER2 Testing in Breast Cancer. Journal of Clinical Oncology, 29, e458. https://doi.org/10.1200/JCO.2011.35.2245
[18]
Sakr, R.A., Barbashina, V., Morrogh, M., Chandarlapaty, S., Andrade, V.P., Arroyo, C.D., et al. (2010) Protocol for PTEN Expression by Immunohistochemistry in Formalin-Fixed Paraffin-Embedded Human Breast Carcinoma. Applied Immunohistochemistry & Molecular Morphology, 18, 371-374.
https://doi.org/10.1097/PAI.0b013e3181d50bd5
[19]
Lopez, G., Noale, M., Corti, C., Gaudioso, G., Sajjadi, E., Venetis, K., et al. (2020) PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer. International Journal of Molecular Sciences, 21, 1461.
https://doi.org/10.3390/ijms21041461
[20]
Al-Rikabi, A. and Husain, S. (2012) Increasing Prevalence of Breast Cancer among Saudi Patients Attending a Tertiary Referral Hospital: A Retrospective Epidemiologic Study. Croatian Medical Journal, 53, 239-243.
https://doi.org/10.3325/cmj.2012.53.239
[21]
Albasri, A., Hussainy, A.S., Sundkji, I. and Alhujaily, A. (2014) Histopathological Features of Breast Cancer in Al-Madinah Region of Saudi Arabia. Saudi Medical Journal, 35, 1489-1493.
[22]
Alabdulkarim, B., Hassanain, M., Bokhari, A., AlSaif, A. and Alkarji, H. (2018) Age Distribution and Outcomes in Patients Undergoing Breast Cancer Resection in Saudi Arabia. A Single-Institute Study. Saudi Medical Journal, 39, 464-469.
https://doi.org/10.15537/smj.2018.5.21993
[23]
Al-Thoubaity, F.K. (2020) Molecular Classification of Breast Cancer: A Retrospective Cohort Study. Annals of Medicine and Surgery, 49, 44-48.
https://doi.org/10.1016/j.amsu.2019.11.021
[24]
Salmena, L., Carracedo, A. and Pandolfi, P.P. (2008) Tenets of PTEN Tumor Suppression. Cell, 133, 403-414. https://doi.org/10.1016/j.cell.2008.04.013
[25]
Rimawi, M.F., De Angelis, C., Contreras, A., Pareja, F., Geyer, F.C., Burke, K.A., et al. (2018) Low PTEN Levels and PIK3CA Mutations Predict Resistance to Neoadjuvant Lapatinib and Trastuzumab without Chemotherapy in Patients with HER2 Over-Expressing Breast Cancer. Breast Cancer Research and Treatment, 167, 731-740.
https://doi.org/10.1007/s10549-017-4533-9
[26]
Constantinou, C., Papadopoulos, S., Karyda, E., Alexopoulos, A., Agnanti, N., Batistatou, A., et al. (2018) Expression and Clinical Significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in Triple-Negative Breast Cancer—A Single Centre Prospective Observational Study. In Vivo (Athens Greece), 32, 303-311. https://doi.org/10.21873/invivo.11238
[27]
She, Q.-B., Gruvberger-Saal, S., Maurer, M., Chen, Y., Jumppanen, M., Su, T., et al. (2016) Integrated Molecular Pathway Analysis Informs a Synergistic Combination Therapy Targeting PTEN/PI3K and EGFR Pathways for Basal-Like Breast Cancer. BMC Cancer, 16, 587. https://doi.org/10.1186/s12885-016-2609-2
[28]
Bazzichetto, C., Conciatori, F., Pallocca, M., Falcone, I., Fanciulli, M., Cognetti, F., et al. (2019) PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise? Cancers, 11, 435. https://doi.org/10.3390/cancers11040435
[29]
Li, G., Guo, X., Chen, M., Tang, L., Jiang, H., Day, J.X., et al. (2018) Prevalence and Spectrum of AKT1, PIK3CA, PTEN and TP53 Somatic Mutations in Chinese Breast Cancer Patients. PLoS ONE, 13, e0203495.
https://doi.org/10.1371/journal.pone.0203495
[30]
Saal, L.H., Johansson, P., Holm, K., Gruvberger-Saal, S.K., She, Q.-B., Maurer, M., et al. (2007) Poor Prognosis in Carcinoma Is Associated with a Gene Expression Signature of Aberrant PTEN Tumor Suppressor Pathway Activity. Proceedings of the National Academy of Sciences of the United States of America, 104, 7564-7569.
https://doi.org/10.1073/pnas.0702507104
[31]
Jia, L., Yang, X., Tian, W., Guo, S., Huang, W. and Zhao, W. (2018) Increased Expression of c-Met Is Associated with Chemotherapy-Resistant Breast Cancer and Poor Clinical Outcome. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 24, 8239-8249.
https://doi.org/10.12659/MSM.913514
[32]
Yan, S., Jiao, X., Zou, H. and Li, K. (2015) Prognostic Significance of c-Met in Breast Cancer: A Meta-Analysis of 6010 Cases. Diagnostic Pathology, 10, 62.
https://doi.org/10.1186/s13000-015-0296-y
[33]
Organ, S. and Tsao, M.-S. (2011) An Overview of the c-MET Signaling Pathway. Therapeutic Advances in Medical Oncology, 3, S7-S19.
https://doi.org/10.1177/1758834011422556
[34]
Liu, S., Meric-Bernstam, F., Parinyanitikul, N., Wang, B., Eterovic, A.K., Zheng, X., et al. (2015) Functional Consequence of the MET-T1010I Polymorphism in Breast Cancer. Oncotarget, 6, 2604-2614. https://doi.org/10.18632/oncotarget.3094
[35]
Jansson, S., Bendahl, P.-O., Grabau, D.A., Falck, A.-K., Fernö, M., Aaltonen, K., et al. (2014) The Three Receptor Tyrosine Kinases c-KIT, VEGFR2 and PDGFRα, Closely Spaced at 4q12, Show Increased Protein Expression in Triple-Negative Breast Cancer. PLoS ONE, 9, e102176. https://doi.org/10.1371/journal.pone.0102176
[36]
Abbaspour Babaei, M., Kamalidehghan, B., Saleem, M., Huri, H.Z. and Ahmadipour, F. (2016) Receptor Tyrosine Kinase (c-Kit) Inhibitors: A Potential Therapeutic Target in Cancer Cells. Drug Design, Development and Therapy, 10, 2443-2459.
https://doi.org/10.2147/DDDT.S89114
[37]
Deng, L., Zhu, X., Sun, Y., Wang, J., Zhong, X., Li, J., et al. (2019) Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients. Cancer Research and Treatment, 51, 128-140. https://doi.org/10.4143/crt.2017.598
[38]
Fleisher, B., Clarke, C. and Ait-Oudhia, S. (2016) Current Advances in Biomarkers for Targeted Therapy in Triple-Negative Breast Cancer. Breast Cancer, 8, 183-197.
https://doi.org/10.2147/BCTT.S114659
[39]
Luo, Y., Huang, W., Zhang, H. and Liu, G. (2018) Prognostic Significance of CD117 Expression and TP53 Missense Mutations in Triple-Negative Breast Cancer. Oncology Letters, 15, 6161-6170. https://doi.org/10.3892/ol.2018.8104
